On January 17, 2023 Biocure Technology Inc. ("CURE" or the "Company") (CSE:CURE) BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") reported that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 12,500 shares at 4.328CAD per share for gross proceeds of $54,100 (Press release, Biocure Technology, JAN 17, 2023, View Source [SID1234628741]). All dollar values are based on the published Exchange Rate of CAD0.001082/KRW1 on January 13, 2023, Bank of Canada. After the issuance of new BPK shares, CURE holds now 93.42% interest in BPK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The net proceeds from the non-brokered private placement are intended to be used for general working capital.